- IN₹313.14bn
- IN₹509.31bn
- IN₹111.74bn
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 31.58 | ||
PEG Ratio (f) | 1.22 | ||
EPS Growth (f) | 34.8% | ||
Dividend Yield (f) | 0.46% |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 1.65 | ||
Price to Tang. Book | n/a | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 2.14 | ||
EV to EBITDA | 14.96 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 4.25% | ||
Return on Equity | 8.39% | ||
Operating Margin | 12.86% |
Financial Summary
Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | IN₹m | 55,144 | 63,005 | 71,431 | 81,840 | 111,742 | 145,799.27 | 167,292.84 | 22.03% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +145.75 | -20.42 | -16.87 | +17.08 | -27.17 | +41.44 | +34.8 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Biocon Limited is an India-based biopharmaceutical company, which focuses on treating diabetes, cancer and autoimmune diseases. Its segment includes Generics, Biosimilars, Novel Biologics and Research Services. It has developed and commercialized novel biologics, biosimilars, and complex small molecule active pharmaceutical ingredients (APIs) in India and several key global markets, as well as Generic Formulations in the United Sates, Europe and key emerging markets. Its API portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology and other key products. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. It has over five facilities across Bangalore, Hyderabad and Visakhapatnam in India. Its API manufacturing facilities leverage complex technology platforms that range from microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis and HPAPIs.
Directors
- Kiran Mazumdar-Shaw CHM (68)
- Siddharth Mittal CEO (42)
- John Shaw NVC (72)
- Shreehas Tambe CEX
- Amitava Saha CHO
- Mayank Verma CCO
- Sriram A.V. OTH
- Seema Ahuja OTH
- Gopala Dasika OTH
- Prasad Deshpand OTH
- Vivek Gupta OTH
- Manoj Pananchukunnath OTH
- Paul Thomas OTH
- Nehal Vora OTH
- Abhijit Zutshi OTH
- Eric Mazumdar NED
- Ravi Mazumdar NED (66)
- Daniel Bradbury NID (60)
- Meleveetil Damodaran NID (74)
- Mary Harney NID (68)
- Vijay Kuchroo NID (66)
- Bobby Parikh NID (57)
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 29th, 1978
- Public Since
- April 17th, 2004
- No. of Shareholders
- 421,688
- No. of Employees
- 3,408
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 1,196,804,982
- Address
- 20th KM, Hosur Road, Electronic City,, BANGALORE, 560100
- Web
- https://www.biocon.com/
- Phone
- +91 8028082808
- Auditors
- BSR & Co. LLP
Upcoming Events for BIOCON
Full Year 2024 Biocon Ltd Earnings Call
Q1 2025 Biocon Ltd Earnings Release
Biocon Ltd Annual Shareholders Meeting
Similar to BIOCON
Suven Life Sciences
National Stock Exchange of India
Syngene International
National Stock Exchange of India
Take Solutions
National Stock Exchange of India
Vimta Labs
National Stock Exchange of India
FAQ
As of Today at 19:04 UTC, shares in Biocon are trading at IN₹261.65. This share price information is delayed by 15 minutes.
Shares in Biocon last closed at IN₹261.65 and the price had moved by +14.01% over the past 365 days. In terms of relative price strength the Biocon share price has underperformed the S&P BSE 100 Index by -11.57% over the past year.
The overall consensus recommendation for Biocon is Hold. You can view the full broker recommendation list by unlocking its StockReport.
The Biocon dividend yield is 0.57% based on the trailing twelve month period.
Last year, Biocon paid a total dividend of IN₹1.50, and it currently has a trailing dividend yield of 0.57%. We do not have any data on when Biocon is to next pay dividends.
We do not have data on when Biocon is to next pay dividends. The historic dividend yield on Biocon shares is currently 0.57%.
To buy shares in Biocon you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹261.65, shares in Biocon had a market capitalisation of IN₹313.14bn.
Here are the trading details for Biocon:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: BIOCON
Based on an overall assessment of its quality, value and momentum Biocon is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Biocon is IN₹282.61. That is 8.01% above the last closing price of IN₹261.65.
Analysts covering Biocon currently have a consensus Earnings Per Share (EPS) forecast of IN₹6.15 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biocon. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -3.19%.
As of the last closing price of IN₹261.65, shares in Biocon were trading +1.03% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Biocon PE ratio based on its reported earnings over the past 12 months is 31.58. The shares last closed at IN₹261.65.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Biocon's management team is headed by:
- Kiran Mazumdar-Shaw - CHM
- Siddharth Mittal - CEO
- John Shaw - NVC
- Shreehas Tambe - CEX
- Amitava Saha - CHO
- Mayank Verma - CCO
- Sriram A.V. - OTH
- Seema Ahuja - OTH
- Gopala Dasika - OTH
- Prasad Deshpand - OTH
- Vivek Gupta - OTH
- Manoj Pananchukunnath - OTH
- Paul Thomas - OTH
- Nehal Vora - OTH
- Abhijit Zutshi - OTH
- Eric Mazumdar - NED
- Ravi Mazumdar - NED
- Daniel Bradbury - NID
- Meleveetil Damodaran - NID
- Mary Harney - NID
- Vijay Kuchroo - NID
- Bobby Parikh - NID